SOUTH SAN FRANCISCO, Calif., March 8 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it will hold a conference call to provide a corporate and year-end financial update, including an update on the clinical development plan for picoplatin, the Company's lead product candidate. Jerry McMahon, Ph.D., chairman, president and CEO of Poniard, will host the call beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on Thursday, March 15.
Teleconference/Webcast Details
To participate in the live call by telephone, please dial 800-289-0529 from the U.S. or +1-913-981-5523 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay will also be available online for 14 days following the live presentation.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancers. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.
(C) 2007 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.
Poniard Pharmaceuticals, Inc.CONTACT: Julie Rathbun of Poniard Pharmaceuticals CorporateCommunications, +1-206-286-2517, jrathbun@poniard.com
Web site: http://www.poniard.com//
